Pharmacology for Nurses · Heart Failure Drugs
Adjunct Medications Used in Heart Failure
On this page 9 sections
In 30 seconds
Heart failure (HF) is a syndrome in which the heart cannot pump enough blood to meet the body's needs. Guideline-directed therapy for HF with reduced ejection fraction rests on neurohormonal blockade — ACE inhibitors/ARBs/ARNIs, beta-blockers, mineralocorticoid receptor antagonists, and SGLT2 inhibitors — plus diuretics for congestion. Adjunct medications are the additional agents layered onto that foundation when people remain symptomatic, cannot tolerate a cornerstone drug, or need short-term hemodynamic support. They include digoxin (stronger contraction, slower heart rate), ivabradine (a pure rate-lowering agent), hydralazine + isosorbide dinitrate (dual vasodilation), vericiguat (a cGMP-pathway stimulator), and short-term intravenous inotropes (dobutamine, milrinone) for acute decompensation. None of these replace the cornerstone drugs; each fills a specific gap.
Why this matters
Heart failure affects millions of people and drives frequent hospital readmissions, so nurses meet these drugs on general units and in critical care. Most people with HFrEF take four or more cardiovascular drugs, and each adjunct was added for a reason that changes how you assess them: digoxin toxicity can masquerade as "just feeling unwell," ivabradine can push the heart rate too low, and inotropes carry arrhythmia risk. Exams test the match between mechanism and drug, key toxicities, and which adjunct fits which clinical gap. This guide covers drug classes and mechanisms only; doses, monitoring schedules, and administration rules vary by institution and must always be verified against current references, the formulary, and prescriber orders.
The college version
Core Concepts
Digoxin: more force, slower rate
Digoxin inhibits the sodium-potassium ATPase pump on cardiac cells. With the pump partially blocked, intracellular sodium rises, the sodium-calcium exchanger runs in reverse, more calcium enters the cell, and contraction strengthens (positive Inotropy The strength of the heart's contraction Full entry →). Digoxin also increases vagal tone, slowing AV-node conduction — useful for rate control in atrial fibrillation. It has a Narrow therapeutic index A small margin between effective and toxic drug levels Full entry → — a small gap between effective and toxic levels. Classic toxicity signals include GI upset (nausea, anorexia), visual disturbances such as yellow-green halos, and new dysrhythmias; hypokalemia raises toxicity risk because the pump is already struggling. Monitoring parameters vary by institution and must be verified against current references.
Ivabradine: rate without losing force
Ivabradine blocks the "funny" current (If) in the sinoatrial node — the pacemaker current that drives resting heart rate. The result is a slower sinus rate with no direct effect on contractility and no blood-pressure lowering, which distinguishes it from beta-blockers. It is used in selected people with HFrEF who remain symptomatic with an elevated resting sinus rate despite optimal therapy. Because it acts on the sinus node's pacemaker current rather than AV conduction, it is not a rate-control option in atrial fibrillation; check contraindications against current product information. The key nursing point is heart-rate monitoring: a rate that drifts too low is the effect to watch for.
Hydralazine + isosorbide dinitrate: unloading from both ends
This combination works from the vascular side. Hydralazine relaxes arterioles, reducing Afterload The resistance the ventricle must overcome to eject blood (the resistance the heart pushes against), letting a weakened ventricle empty more easily. Isosorbide dinitrate relaxes veins, reducing Preload The volume of blood returning to the heart (blood returning to the heart), lowering filling pressures and easing congestion. The combination has an evidence base in people with HFrEF who self-identify as Black, and it is also used when ACE inhibitors or ARBs cannot be tolerated. A key exam point: hydralazine alone can trigger reflex tachycardia and fluid retention — the pair, not either drug by itself, is the therapy.
Vericiguat: boosting cGMP signaling
Vericiguat is a soluble guanylate cyclase (sGC) stimulator. It directly stimulates the enzyme that produces cyclic GMP, a signaling molecule that promotes vasodilation and may counter maladaptive cardiac remodeling. It is an oral adjunct for people with HFrEF who have had a recent worsening episode despite standard therapy. It acts at the enzyme level rather than by donating nitric oxide (as nitrates do), and its place in therapy continues to evolve, so institution-specific protocols apply.
Intravenous inotropes: rescue support in acute decompensation
When a person decompensates into a low-output state — falling blood pressure, worsening kidney function, altered mentation — short-term IV support may be needed in a monitored (often ICU) setting. Dobutamine stimulates beta-1 receptors, increasing contractility and heart rate. Milrinone inhibits phosphodiesterase-3, raising cAMP in cardiac muscle and vessels, increasing contractility and causing vasodilation. Both are bridges, not destinations, and both can provoke dysrhythmias, hypotension, or worsening ischemia — they are used only per protocol and prescriber orders.
Common Confusions
| Do Not Confuse | With | Difference |
|---|---|---|
| Digoxin's inotropy | Digoxin's rate control | Inotropy comes from Na⁺/K⁺-ATPase inhibition (more intracellular calcium); rate control from increased vagal tone on the AV node |
| Ivabradine | A beta-blocker | Both lower heart rate, but ivabradine acts only on the SA-node If current: no inotropy, no BP effect, no use in atrial fibrillation |
| Hydralazine + nitrate | Hydralazine alone | The pair unloads afterload and preload; hydralazine alone risks reflex tachycardia and fluid retention |
| Dobutamine | Milrinone | Dobutamine is a beta-1 agonist; milrinone is a PDE3 inhibitor (contractility + vasodilation via cAMP) |
| Inotropes | Vasopressors | Inotropes increase contractility; vasopressors raise BP by constricting vessels — different drugs, different problems |
Eli explains
The same idea, in plain words
Explain it like I’m 10
Imagine the heart is a water pump that has gotten weak. The main medicines relax the pipes and stop the "stress hormones" from squeezing too hard. The extra medicines are special tools: digoxin gives the pump a stronger push, ivabradine stops the pump from rushing, hydralazine and the nitrate make the pipes easier to push against, and the IV medicines are emergency boosts used only in the hospital. Each tool fixes one specific problem — but every tool can cause trouble if used wrong.
Worked example
Mrs. Alvarez, 68, has HFrEF and takes an ACE inhibitor, a beta-blocker, an SGLT2 inhibitor, and furosemide. She still feels short of breath on stairs, and her resting sinus rate is 92 despite the beta-blocker, so her clinician adds ivabradine. A month later she calls the clinic feeling nauseated and "seeing yellow halos." The nurse keeps mechanisms straight: ivabradine slows rate (a pulse in the 50s is its expected effect), while nausea plus visual changes points to digoxin toxicity — but she is not on digoxin. When the prescriber later adds digoxin, the same nurse checks potassium and watches for GI and visual complaints, since hypokalemia and a narrow therapeutic index make toxicity a real possibility. The scenario shows why mechanism-based thinking beats memorizing names: the same symptom means different things depending on which adjunct is on board.
Key takeaways
- Adjuncts add to — never replace — the core HF drugs (RAAS blockade, beta-blockers, MRAs, SGLT2 inhibitors, diuretics).
- Digoxin = positive inotrope + vagal rate control; narrow therapeutic index; toxicity signals: GI upset, visual halos, dysrhythmias; hypokalemia raises risk.
- Ivabradine slows sinus rate via the If current — no inotropy, no BP effect; not for rate control in atrial fibrillation.
- Hydralazine + isosorbide dinitrate = afterload + preload reduction; hydralazine alone can cause reflex tachycardia and fluid retention.
- Vericiguat stimulates sGC → more cGMP → vasodilation and anti-remodeling effects; used after recent worsening episodes.
- Dobutamine (beta-1 agonist) and milrinone (PDE3 inhibitor) are short-term IV rescue agents for low-output states; arrhythmia and ischemia risk; monitored settings only.
- Verify doses, monitoring parameters, and administration rules against current references, the formulary, and prescriber orders.
Check yourself
5 review questions from the chapter. Try each one, then open the answer.
Why is digoxin a "positive inotrope," and what pump does it inhibit?
Show answer
Digoxin increases contraction force by inhibiting the sodium-potassium ATPase pump, which indirectly raises intracellular calcium available for contraction.
A person with HFrEF has a resting sinus rate of 95 despite a beta-blocker. Which adjunct targets exactly this problem?
Show answer
Ivabradine — it blocks the If ("funny") current in the sinoatrial node, slowing sinus rate without reducing contractility or blood pressure.
Why is hydralazine combined with isosorbide dinitrate rather than used alone?
Show answer
Hydralazine lowers afterload but alone can cause reflex tachycardia and fluid retention; the nitrate adds preload reduction, and the combination is the studied therapy.
List three classic signals of digoxin toxicity and the electrolyte disturbance that makes toxicity more likely.
Show answer
GI upset (nausea, anorexia), visual disturbances such as yellow-green halos, and new dysrhythmias; hypokalemia increases the risk.
What distinguishes dobutamine from milrinone at the mechanism level, and where are these drugs used?
Show answer
Dobutamine is a beta-1 agonist that increases contractility (and rate); milrinone is a PDE3 inhibitor that raises cAMP, increasing contractility and causing vasodilation. Both are short-term IV rescue agents for acute low-output decompensation in monitored settings.
Study tools & related lessonsKey vocabulary · Related
Key vocabulary
- Inotropy
- The strength of the heart's contraction
- Afterload
- The resistance the ventricle must overcome to eject blood
- Preload
- The volume of blood returning to the heart
- Narrow therapeutic index
- A small margin between effective and toxic drug levels
- If ("funny") current
- The SA-node pacemaker current that drives resting heart rate
- cGMP
- A signaling molecule that relaxes blood vessels
- PDE3 inhibitor
- A drug that blocks the enzyme breaking down cAMP
Sources & references
This lesson was adapted from the open educational references above; their licenses and attributions are preserved. See Copyright & Licensing.
Educational content only. It is not medical, legal or professional advice. Found an error? Tell us.